United Therapeutics downgraded by Wells Fargo
$UTHR
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo downgraded United Therapeutics from Overweight to Equal Weight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/25/2025 | Overweight → Equal Weight | Wells Fargo | |
| 4/21/2025 | $314.00 | Underperform → Neutral | BofA Securities |
| 7/11/2024 | $310.00 → $321.00 | Overweight → Equal-Weight | Morgan Stanley |
| 2/12/2024 | $213.00 → $215.00 | Sell → Neutral | Goldman |
| 2/5/2024 | $330.00 | Outperform | Leerink Partners |
| 12/8/2023 | $309.00 | Overweight | Wells Fargo |
| 12/6/2022 | $320.00 | Buy | UBS |
| 12/5/2022 | $230.00 | Sell | Goldman |
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. "2025 is off to a tremendous start as we reported yet another quarter of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we'll progress our innovation and revolution waves of growth with the readout
Interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open-label study to be presented at a mini symposium An annual update of the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented at a poster session United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Francisco on May 16-21, 2025. At ATS, United Therapeutics is sponsoring several events including the Respiratory Innovation Summit and the
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, April 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and missi
WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. "2025 is off to a tremendous start as we reported yet another quarter of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we'll progress our innovation and revolution waves of growth with the readout
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, April 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and missi
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a record $2.88 billion, reflecting 24% growth over 2023. "I want to congratulate every Unitherian for their relentless dedication, which has allowed us to deliver a third consecutive year of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "On top of that, our three-year cascade of clinical and regulatory events is under way: both TETON studies in idiopathic pulmonary fibrosis are enrolled, facilitating data starting the second half
8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)
10-Q - UNITED THERAPEUTICS Corp (0001082554) (Filer)
DEFA14A - UNITED THERAPEUTICS Corp (0001082554) (Filer)
Wells Fargo downgraded United Therapeutics from Overweight to Equal Weight
BofA Securities upgraded United Therapeutics from Underperform to Neutral and set a new price target of $314.00
Morgan Stanley downgraded United Therapeutics from Overweight to Equal-Weight and set a new price target of $321.00 from $310.00 previously
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)